ArticleCureus2024
Efficacy of Oral Sirolimus Therapy for Adult Orbital Slow-Flow Vascular Malformations: A Volumetric Evaluation.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Somatic Driver to Molecular Therapy in Retinal, Choroidal and Periocular Vascular Disease: Mosaicism, Targetable Pathways and Ocular Toxicity.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orbital lymphatic malformations significantly impair visual function, with inflammation contributing to corneal dryness and diplopia due to exophthalmos. Disease progression may lead to blindness, and in severe cases, exenteration may be required. We treated two symptomatic cases of adult orbital slow-flow vascular malformations with oral sirolimus. Although the patients maintained good visual acuity before treatment, prominent exophthalmos posed a substantial risk to visual function. After medication, eyeball proptosis improved significantly in all cases, with magnetic resonance imaging volumetry analysis showing a reduction of 28.5% to 82.1%. This treatment demonstrated minimal side effects and may serve as an initial therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.